BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47. [PMID: 8834023 DOI: 10.1016/s0168-8278(96)80184-x] [Cited by in Crossref: 334] [Cited by in F6Publishing: 79] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K, Mu Y. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol 2022;13:949003. [DOI: 10.3389/fendo.2022.949003] [Reference Citation Analysis]
2 Ohdo S, Koyanagi S, Matsunaga N. Chronopharmacology of immune-related diseases. Allergol Int 2022:S1323-8930(22)00075-2. [PMID: 35850747 DOI: 10.1016/j.alit.2022.06.006] [Reference Citation Analysis]
3 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci 2021;22:13578. [PMID: 34948375 DOI: 10.3390/ijms222413578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
5 Mo Z, Tang J, Wu Z, Chen D, Xie D, Wang P. Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review. Liver Research 2021;5:97-101. [DOI: 10.1016/j.livres.2021.04.001] [Reference Citation Analysis]
6 Gull I, Aslam MS, Tipu I, Mushtaq R, Ali TZ, Athar MA. Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection. Sci Rep 2019;9:10867. [PMID: 31350425 DOI: 10.1038/s41598-019-47074-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Essali N, Goldsmith DR, Carbone L, Miller BJ. Psychosis as an adverse effect of monoclonal antibody immunotherapy. Brain Behav Immun 2019;81:646-9. [PMID: 31170448 DOI: 10.1016/j.bbi.2019.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
8 Chang YK, Tseng YT, Chen KH, Chen KT. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord 2019;19:36. [PMID: 30953492 DOI: 10.1186/s12902-019-0362-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yen H, Chi CC. Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2019;20:31-40. [PMID: 30317450 DOI: 10.1007/s40257-018-0394-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
10 Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M. Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clin Infect Dis 2017;65:864-6. [PMID: 28505305 DOI: 10.1093/cid/cix441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sayiner ZA, Eraydın A, Metin T, Özkaya M. Interferon alpha-induced non-immune thyrotoxicosis treated by plasmapheresis. BMJ Case Rep 2017;2017:bcr-2017-221228. [PMID: 28951513 DOI: 10.1136/bcr-2017-221228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Nishida T. Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. J Endocr Soc 2017;1:886-96. [PMID: 29264539 DOI: 10.1210/js.2017-00183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
13 Gould TD, Georgiou P, Brenner LA, Brundin L, Can A, Courtet P, Donaldson ZR, Dwivedi Y, Guillaume S, Gottesman II, Kanekar S, Lowry CA, Renshaw PF, Rujescu D, Smith EG, Turecki G, Zanos P, Zarate CA Jr, Zunszain PA, Postolache TT. Animal models to improve our understanding and treatment of suicidal behavior. Transl Psychiatry 2017;7:e1092. [PMID: 28398339 DOI: 10.1038/tp.2017.50] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
14 Baik SJ, Kim TH, Kim HI, Rhie JY. Myasthenia Crisis Induced by Pegylated-Interferon in Patient With Chronic Hepatitis C: A Case Report. Medicine (Baltimore) 2016;95:e3782. [PMID: 27227948 DOI: 10.1097/MD.0000000000003782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
15 Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38:1153-1168. [PMID: 26370106 DOI: 10.1007/s40264-015-0339-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
16 Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Sharafi H. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e37011. [PMID: 27630727 DOI: 10.5812/hepatmon.37011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus--why the β cells? Nat Rev Endocrinol 2016;12:263-73. [PMID: 27020257 DOI: 10.1038/nrendo.2016.30] [Cited by in Crossref: 146] [Cited by in F6Publishing: 120] [Article Influence: 24.3] [Reference Citation Analysis]
18 Spindelboeck W, Horvath A, Tawdrous M, Schmerböck B, Zettel G, Posch A, Streit A, Jurse P, Lemesch S, Horn M, Wuensch G, Stiegler P, Stauber RE, Leber B, Stadlbauer V. Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS One 2016;11:e0150299. [PMID: 26938078 DOI: 10.1371/journal.pone.0150299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22(4): 1650-1663 [PMID: 26819530 DOI: 10.3748/wjg.v22.i4.1650] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
20 Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses. 2015;7:4960-4977. [PMID: 26389937 DOI: 10.3390/v7092854] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
21 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
22 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
23 Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, Antonelli A, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol 2015; 7(3): 327-343 [PMID: 25848462 DOI: 10.4254/wjh.v7.i3.327] [Cited by in Crossref: 100] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
24 Sakatani A, Doi Y, Matsuda T, Sasai Y, Nishida N, Sakamoto M, Uenoyama N, Matsumoto Y, Kinoshita K. Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C. World J Gastroenterol 2015; 21(9): 2826-2829 [PMID: 25759556 DOI: 10.3748/wjg.v21.i9.2826] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161:546-53. [PMID: 25329202 DOI: 10.7326/M14-0602] [Cited by in Crossref: 65] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
26 Cashman CR, Höke A. Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett. 2015;596:33-50. [PMID: 25617478 DOI: 10.1016/j.neulet.2015.01.048] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 15.9] [Reference Citation Analysis]
27 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
28 Che JW, Kraft AR, Selin LK, Welsh RM. Regulatory T cells resist virus infection-induced apoptosis. J Virol 2015;89:2112-20. [PMID: 25473049 DOI: 10.1128/JVI.02245-14] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
29 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
30 Igawa T, Fushimi S, Matsuo R, Ikeda F, Nouso K, Yoshino T, Nakatsukasa H. Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report. Clin J Gastroenterol 2014;7:465-70. [PMID: 26184030 DOI: 10.1007/s12328-014-0527-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Sato A, Yamauchi M, Yamada T, Kumano R, Adachi K, Ishii T, Hayashi M, Kumon D. Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia. Clin J Gastroenterol 2014;7:355-60. [PMID: 25132867 DOI: 10.1007/s12328-014-0500-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Allam M, Riad H. Concise review of recent studies in vitiligo. Qatar Med J 2013;2013:1-19. [PMID: 25003059 DOI: 10.5339/qmj.2013.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
33 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:713-728. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
34 Lotrich FE. Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry 2013;170:592-7. [PMID: 23732965 DOI: 10.1176/appi.ajp.2013.12121572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Alsabbagh ME, Eisa N, Alraiyes AH, Alraies MC. Chronic hepatitis C therapy: a rare complication revisited. BMJ Case Rep. 2013;2013:bcr2013200514. [PMID: 23893287 DOI: 10.1136/bcr-2013-200514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci 2013;10:1015-21. [PMID: 23801888 DOI: 10.7150/ijms.6402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
37 Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF, Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 2013;32:316-23. [PMID: 23715642 DOI: 10.1007/s12664-013-0336-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
38 Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One 2013;8:e58975. [PMID: 23533595 DOI: 10.1371/journal.pone.0058975] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
39 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
40 Gravina AG, Federico A, Masarone M, Cuomo A, Tuccillo C, Loguercio C, Persico M, Romano M. Coeliac disease and C virus-related chronic hepatitis: a non association. BMC Res Notes. 2012;5:533. [PMID: 23009068 DOI: 10.1186/1756-0500-5-533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
41 Schwarz MJ. Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialogues Clin Neurosci 2003;5:139-53. [PMID: 22034110 [PMID: 22034110 DOI: 10.31887/dcns.2003.5.2/mschwarz] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM. Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav 2012;2:525-31. [PMID: 23139898 DOI: 10.1002/brb3.72] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
43 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.7326/0003-4819-156-4-201202210-00005] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 14.2] [Reference Citation Analysis]
44 Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290. [PMID: 22351713 DOI: 10.1059/0003-4819-156-4-201202210-00005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Potts JR, Atkinson S, Aram JA, Tibble J, Davies KA, Verma S. De novo Cryoglobulinaemic Mononeuritis Multiplex during Treatment of Chronic Hepatitis C Infection: A Viral Effect or Induced by Pegylated Interferon Alpha? Case Rep Gastroenterol 2012;6:155-61. [PMID: 22679403 DOI: 10.1159/000337871] [Reference Citation Analysis]
46 Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6:e26783. [PMID: 22164204 DOI: 10.1371/journal.pone.0026783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
47 Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011;103:1572-87. [PMID: 22010182 DOI: 10.1093/jnci/djr373] [Cited by in Crossref: 104] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
48 Skabelund AJ, Hauser TR, Goist KJ. Pure red cell aplasia caused by ribavirin and interferon treatment. Clin J Gastroenterol 2011;4:313-7. [PMID: 26189631 DOI: 10.1007/s12328-011-0235-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
49 Lim JH, Lee YN, Kim YS, Kim SG, Jeong SW, Jang JY, Kim HS, Lee SH, Park TK. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol. 2011;17:61-65. [PMID: 21494079 DOI: 10.3350/kjhep.2011.17.1.61] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
50 Said A, Elbahrawy A, Alfiomy M, Abdellah M, Shahat K, Salah M, Mostafa S, Elwassief A, Aboelfotoh A, Abdelhafeez H, El-Sherif A. Pegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient. BMJ Case Rep 2011;2011:bcr0620114400. [PMID: 22688484 DOI: 10.1136/bcr.06.2011.4400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 9.0] [Reference Citation Analysis]
52 Zhang YL, Cheng T, Cai YJ, Yuan Q, Liu C, Zhang T, Xia DZ, Li RY, Yang LW, Wang YB, Yeo AE, Shih JW, Zhang J, Xia NS. RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo. BMC Microbiol 2010;10:214. [PMID: 20696079 DOI: 10.1186/1471-2180-10-214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
53 Tovey MG, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel) 2010;3:1162-86. [PMID: 27713294 DOI: 10.3390/ph3041162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
54 Lotrich F. Management of Psychiatric Disease in Hepatitis C Treatment Candidates. Curr Hepat Rep 2010;9:113-8. [PMID: 20871787 DOI: 10.1007/s11901-010-0035-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
55 Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010;59:1059-71. [PMID: 20217081 DOI: 10.1007/s00262-010-0831-3] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 5.6] [Reference Citation Analysis]
56 Kong YC, Wei WZ, Tomer Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann N Y Acad Sci 2010;1183:222-36. [PMID: 20146718 DOI: 10.1111/j.1749-6632.2009.05138.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
57 Barut S, Karaer H, Oksuz E, Eken AG, Basak AN. Bell’s palsy and choreiform movements during peginterferon α and ribavirin therapy. World J Gastroenterol 2009; 15(29): 3694-3696 [PMID: 19653353 DOI: 10.3748/wjg.15.3694] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci. 2010;55:579-585. [PMID: 19399621 DOI: 10.1007/s10620-009-0797-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
59 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2195] [Cited by in F6Publishing: 1960] [Article Influence: 168.8] [Reference Citation Analysis]
60 Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma. Acta Oncol 2009;48:154-6. [PMID: 19101828 DOI: 10.1080/02841860802047403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
61 Keck K, Volper EM, Spengler RM, Long DD, Chan CY, Ding Y, McCaffrey AP. Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency. Mol Ther. 2009;17:538-547. [PMID: 19088704 DOI: 10.1038/mt.2008.273] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
62 Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009;24:55-68. [PMID: 19067144 DOI: 10.1007/s11011-008-9114-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
63 Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 2009;247:675-80. [PMID: 19034483 DOI: 10.1007/s00417-008-1002-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
64 Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci 2009;54:1369-72. [PMID: 18770036 DOI: 10.1007/s10620-008-0476-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Schäfer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007;16:186-201. [PMID: 18188838 DOI: 10.1002/mpr.229] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
66 Jolobe OM. Patients with old left bundle-branch block and acute coronary syndromes. Br J Hosp Med (Lond) 2007;68:682. [PMID: 18193556 DOI: 10.12968/hmed.2007.68.12.682a] [Reference Citation Analysis]
67 Sangwaiya A, Chan J, Ash S. Depression and hepatitis C. Br J Hosp Med (Lond) 2007;68:682. [PMID: 18186414 DOI: 10.12968/hmed.2007.68.12.682] [Reference Citation Analysis]
68 Kartal ED, Alpat SN, Ozgunes I, Usluer G. Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Adv Ther 2007;24:963-71. [PMID: 18029321 DOI: 10.1007/BF02877700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
69 Hernandez L, Johnson TC, Naiyer AJ, Kryszak D, Ciaccio EJ, Min A, Bodenheimer HC, Brown RS, Fasano A, Green PH. Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci. 2008;53:256-261. [PMID: 17549632 DOI: 10.1007/s10620-007-9851-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
70 Weigand K, Stremmel W, Encke J. Treatment of hepatitis C virus infection. World J Gastroenterol 2007; 13(13): 1897-1905 [PMID: 17461488 DOI: 10.3748/wjg.v13.i13.1897] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
71 Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9. [PMID: 16956917 DOI: 10.1136/gut.2006.102558] [Cited by in Crossref: 227] [Cited by in F6Publishing: 203] [Article Influence: 15.1] [Reference Citation Analysis]
72 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
73 Lodato F, Tamé MR, Colecchia A, Racchini C, Azzaroli F, D’Errico A, Casanova S, Pinna A, Roda E, Mazzella G. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006; 12(26): 4253-4255 [PMID: 16830387 DOI: 10.3748/wjg.v12.i26.4253] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
74 Nozić D. [Successful lamivudine therapy for chronic hepatitis B in the family]. Vojnosanit Pregl 2006;63:504-7. [PMID: 16758804 DOI: 10.2298/vsp0605504n] [Reference Citation Analysis]
75 Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155-174. [PMID: 16451091 DOI: 10.2165/00003495-200666020-00003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
76 Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20. [PMID: 15951552 DOI: 10.1136/gut.2004.057893] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
77 Kendirli T, Kismet E, Demirkaya E, Aydin HI, Kesik V, Köseoğlu V. Death possibly associated with interferon use in a patient with chronic hepatitis. Acta Paediatr 2005;94:984-5. [PMID: 16188832 DOI: 10.1111/j.1651-2227.2005.tb02028.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Beuthien W, Mellinghoff HU, Kempis Jv. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005;24:507-15. [PMID: 15988558 DOI: 10.1007/s10067-005-1093-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
79 Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, Purrington A, Shiffman ML. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-9. [PMID: 15929778 DOI: 10.1111/j.1572-0241.2005.41910.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
80 Rodriguez B, Bobak DA. Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep. 2005;7:91-102. [PMID: 15727735 DOI: 10.1007/s11908-005-0067-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
81 Gatselis NK, Georgiadou SP, Tassopoulos N, Zachou K, Liaskos C, Hatzakis A, Dalekos GN. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study. World J Gastroenterol 2005; 11(4): 482-487 [PMID: 15641130 DOI: 10.3748/wjg.v11.i4.482] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
82 Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5. [PMID: 15558712 DOI: 10.1002/hep.20467] [Cited by in Crossref: 238] [Cited by in F6Publishing: 198] [Article Influence: 13.2] [Reference Citation Analysis]
83 Ohdo S. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety. Drug Saf 2003;26:999-1010. [PMID: 14583062 DOI: 10.2165/00002018-200326140-00002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
84 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. [PMID: 15057920 DOI: 10.1002/hep.20119] [Cited by in Crossref: 1274] [Cited by in F6Publishing: 1122] [Article Influence: 70.8] [Reference Citation Analysis]
85 Chan WB, Chow CC, Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med 2003;96:481-5. [PMID: 14519723 DOI: 10.1258/jrsm.96.10.481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
86 Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003;25:11-20. [PMID: 12661471 DOI: 10.1023/a:1022449613907] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
87 Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9(3): 505-508 [PMID: 12632506 DOI: 10.3748/wjg.v9.i3.505] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
88 Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-51. [PMID: 12540795 DOI: 10.1053/jhep.2003.50031] [Cited by in Crossref: 231] [Cited by in F6Publishing: 222] [Article Influence: 12.2] [Reference Citation Analysis]
89 Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201-S209. [PMID: 12407595 DOI: 10.1002/hep.1840360726] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
90 Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:S201-9. [PMID: 12407595 DOI: 10.1053/jhep.2002.36380] [Cited by in Crossref: 20] [Cited by in F6Publishing: 46] [Article Influence: 1.0] [Reference Citation Analysis]
91 McCulloch M, Broffman M, Gao J, Colford JM Jr. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Public Health 2002;92:1619-28. [PMID: 12356611 DOI: 10.2105/ajph.92.10.1619] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
92 Lebensztejn DM, Kaczmarski M. Lamivudine-associated thrombocytopenia. Am J Gastroenterol 2002;97:2687-8. [PMID: 12385471 DOI: 10.1111/j.1572-0241.2002.06063.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
93 Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-1654. [PMID: 12141831 DOI: 10.1023/A:1015852110353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
94 Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H; Construct Group. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-9. [PMID: 11818693 DOI: 10.1159/000049487] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 5.0] [Reference Citation Analysis]
95 Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf 2001;24:375-84. [PMID: 11419564 DOI: 10.2165/00002018-200124050-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
97 Scalori A, Apale P, Roffi L. Psychological screening before interferon therapy. Hepatology 2001;33:480. [PMID: 11172355 DOI: 10.1002/hep.510330225] [Reference Citation Analysis]
98 Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11. [PMID: 10827143 DOI: 10.1053/jhep.2000.7880] [Cited by in Crossref: 160] [Cited by in F6Publishing: 152] [Article Influence: 7.3] [Reference Citation Analysis]
99 Shinzawa H, Yoshida Y, Masamune O, Toyota T, Takahashi T, Kasukawa R, Sudo T, Ishikawa K, Komatsu M, Ishii M, Takagi T, Hisamichi S, Sato S, Ichida H. Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial. Dig Dis Sci 2000;45:575-80. [PMID: 10749335 DOI: 10.1023/a:1005409627192] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
100 Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8. [PMID: 10716688 DOI: 10.1136/gut.46.4.562] [Cited by in Crossref: 384] [Cited by in F6Publishing: 333] [Article Influence: 17.5] [Reference Citation Analysis]
101 Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:604-5. [PMID: 9918943 DOI: 10.1002/hep.510290246] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
102 Rasch MC, Schellekens H, van Dijck CM, Haagsma EB, Michielsen PP, van Buuren AH, Stötter H, van Hattum J. Tolerance and antiviral effects of high-dose interferon-alpha B/D in patients with chronic hepatitis B. Dig Dis Sci 1998;43:1719-24. [PMID: 9724159 DOI: 10.1023/a:1018823417541] [Reference Citation Analysis]
103 Miossec P. Cytokine-induced autoimmune disorders. Drug Saf 1997;17:93-104. [PMID: 9285200 DOI: 10.2165/00002018-199717020-00002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
104 Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997;53:74-85. [PMID: 9010649 DOI: 10.2165/00003495-199753010-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]